Cart
sales@molnova.com
RRX-001
CAS No. 925206-65-1
RRX-001( RRX001 | RRX 001 )
Catalog No. M16629 CAS No. 925206-65-1
RRX-001 (RRX001) is a novel NO and hypoxia mediated anticancer agent with with epigenetic and immunologic activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 123 | In Stock |
|
| 2MG | 67 | In Stock |
|
| 5MG | 111 | In Stock |
|
| 10MG | 147 | In Stock |
|
| 25MG | 278 | In Stock |
|
| 50MG | 477 | In Stock |
|
| 100MG | 696 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 1451 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRRX-001
-
NoteResearch use only, not for human use.
-
Brief DescriptionRRX-001 (RRX001) is a novel NO and hypoxia mediated anticancer agent with with epigenetic and immunologic activity.
-
DescriptionRRX-001 (RRX001) is a novel NO and hypoxia mediated anticancer agent with with epigenetic and immunologic activity; targets CD133 + /CD44 + cancer stem cells from colon cancer cell-lines, HT-29, Caco-2, and HCT116, and inhibits Wnt pathway signalling with downregulation of c-Myc; inhibits HCT 116 and decreases levels of the DNA methyltransferases DNMT1 and DNMT3a in a time and dose-dependent manner; RRX-001 (RRX001) is a chemosensitizer in multiple tumor types and disease states including malaria, hemorrhagic shock and sickle cell anemia.Lung Cancer Phase 2 Clinical.
-
In VitroCell Viability Assay Cell Line:Human MM-cell lines (MM.1S, RPMI-8226, H929, ARP1, KMS-11, OPM2, LR5, ANBL6.WT), along with drug resistant cell lines such as (MM.1R, Dox40, LR5, ANBL6.BR, RPMI-8226).Concentration:0-5 μM.Incubation Time:24 hours.Result:Induced a dose-dependent significant (p < 0.05) decrease in viability of all cell lines.
-
In VivoAnimal Model:CB-17 SCID-mice were subcutaneously inoculated with 5.0 × 106 MM.1S cells in 100 μL of serum-free RPMI 1640 medium.Dosage:5 mg/kg or 10 mg/kg.Administration:I.V., thrice-weekly for 24 days.Result:Blocked MM tumor growth and enhances survival. Treatment was well tolerated, suggested by no apparent weight loss.Animal Model:Female BALB/c nude mice (19.2?±?1.7?g) based on A549 lung cancer model. Dosage: 10?mg/kg. Administration:IP, twice a week and once a day.Result:Resulted in the most significant tumor growth retardation.Reduction of resident macrophages in tumor-bearing mice attenuates the antitumor activity of RRx-001.
-
SynonymsRRX001 | RRX 001
-
PathwayOthers
-
TargetOther Targets
-
RecptorOther Targets
-
Research AreaCancer
-
IndicationLung Cancer
Chemical Information
-
CAS Number925206-65-1
-
Formula Weight268.023
-
Molecular FormulaC5H6BrN3O5
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 100 mg/mL 373.11 mM
-
SMILESO=[N+](C1([N+]([O-])=O)CN(C(CBr)=O)C1)[O-]
-
Chemical Name2-bromo-1-(3,3-dinitroazetidin-1-yl)ethan-1-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
AD 01
FKBPL (FK506-binding protein like)-based peptide. Binds to and upregulates expression of CD44. Inhibits breast cancer stem cell (BCSC) growth. Decreases pluripotency markers and promotes differentiation of BCSCs. Also inhibits endothelial cell migration as well as tubule and microvessel formation in vitro and in vivo. Blocks tumor growth in xenograft models.
-
Calcitonin, rat
Calcitonin (rat) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development.
-
(20R)-Ginsenoside Rh...
20S, 20R ginsenoside-Rh1 can inhibit the thrombin-induced conversion of fibrinogen to fibrin.
